Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2026-05-28 Investor Presentation
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Investor presentation for Q4/FY26
Investor Presentation Classification · 94% confidence The document begins with a formal SEBI Reg. 30 filing to BSE Limited indicating the submission of an "Earnings Presentation – Q4/FY26." It then includes the full slide deck, with detailed financial highlights, consolidated financials, business overviews, ratios, balance sheet items, cash flow, market opportunities, and strategic positioning. This matches the definition of an Investor Presentation (IP): a detailed presentation for investors focusing on financials, strategy, and market position. It is not merely a short announcement or a press release, nor is it the statutory annual or quarterly report itself, but a slides-based earnings deck. Therefore, it is classified as an Investor Presentation.
2026-05-28 English
Publication of audited financial results for the quarter and financial year ended March 31, 2026.
Interim / Quarterly Report Classification · 75% confidence The document is a SEBI LODR listing filing enclosing “Extract of Audited Financial Results for the quarter and financial year ended March 31, 2026.” It includes detailed tables of quarterly and year-end income, profit, equity, etc., indicating substantive financial data rather than a mere headline release or note that a report has been published. This aligns with our definition of an Interim/Quarterly Report (IR) as a comprehensive financial report for a period shorter than a full fiscal year (here, quarter plus year-end results). FY 2026
2026-05-27 English
Recommendation of final dividend subject to approval of shareholders.
Interim / Quarterly Report Classification · 88% confidence The document is the formal outcome of the Board Meeting under SEBI LODR Reg 30 and 33, approving and publishing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, including the Independent Auditor’s Report and detailed financial statements. It contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and year‐to‐date results), not merely summary highlights or a notice of publication. Therefore it classifies as an Interim/Quarterly Report. FY 2026
2026-05-26 English
Press release regarding audited financial results of FY26.
Earnings Release Classification · 92% confidence The document is a press release dated May 26, 2026 from Fermenta Biotech announcing the company’s audited financial results for the full fiscal year ended March 31, 2026, with key highlights on revenue, EBITDA, PAT, segmental and geographic mix, and an MD commentary. This is a classic earnings release announcing periodical financial results, not the full annual report or interim report. Therefore, it should be classified as an Earnings Release (ER). FY 2026
2026-05-26 English
Intimation regarding proposed re-appointment of director pursuant to retirement by rotation, grant of stock options, application to NSE.
Board/Management Information Classification · 90% confidence The document is a Regulation 30 SEBI (Listing Obligations) disclosure of board and committee decisions: re-appointment of a non-executive director, continuation beyond retirement, approval of ESOP grants, application for NSE listing, and subsidiary private placement. These are announcements of changes in board composition and senior management authorizations, fitting the Board/Management Information category.
2026-05-26 English
Annual General Meeting, Financial Results and Dividend
Interim / Quarterly Report Classification · 90% confidence The document is a SEBI Listing Regulations board meeting outcome letter that includes the audited standalone financial results for the quarter and year ended March 31, 2026, along with the auditor’s report and the full financial statements. This is more than a simple earnings highlight but contains substantive financial data and statements for the quarter and year‐to‐date period. It is not a full annual report, nor merely a publication notice. Therefore this aligns with the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.